Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major Depressive Disorder (MDD) is heterogeneous.
• Identifying specific depressive subtypes may aid treatment selection.
• Previous research has explored various depressive subtypes.

Purpose of the Study:

• To determine the prevalence of melancholic, atypical, and anxious depressive subtypes and their combinations in outpatients with MDD.
• To compare the remission rates and symptom changes in these subtypes after treatment with escitalopram, sertraline, or venlafaxine.

Main Methods:

• 1,008 adult outpatients with MDD were randomized to 8 weeks of escitalopram, sertraline, or venlafaxine.
• Participants were categorized into eight mutually exclusive groups based on subtype criteria (pure, multiple, or no subtype).
• Symptom trajectories were analyzed using mixed-effects models, and remission was assessed via logistic regression.

Main Results:

• 39% of participants had a pure subtype, 36% had multiple subtypes, and 25% had no subtype.
• All subtype groups showed similar significant reductions in depressive symptoms.
• No significant differences in remission rates were observed between subtype groups, and subtype did not moderate treatment effects.

Conclusions:

• Substantial overlap exists among melancholic, atypical, and anxious depressive subtypes.
• All identified subtype groups responded similarly to the three tested antidepressants.
• These findings suggest that depressive subtypes may have limited utility in guiding antidepressant selection.